40Hz light modulation glasses: A one-week flash stimulation therapy (JK-PMEG2700K light modulation glasses \[light source\]) using flash stimulation between 20:00 and 21:00.
100Hz light modulation glasses: A one-week flash stimulation therapy (JK-PMEG2700K light modulation glasses \[light source\]) using flash stimulation between 20:00 and 21:00.
Study summary
The aim of this study was to evaluate the effect of flash stimulation therapy on the function of the cerebral glymphatic system and efficacy of improving symptoms in PD patients.
Eligibility
Sex
ALL
Min age
50 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
1. PD patients who meet the diagnostic criteria of the International Movement Disorders Association (MDS), between the ages of 50 and 70 years, the course of disease ≤5 years, and the Hoehn \& Yahr stage ≤3;
2. Anti-PD drugs were taken regularly for at least one month before screening, and symptoms were stable;
3. The fixed bedtime in the past month is between 9:00 p.m. and 1:00 a.m., and the total sleep time is ≥6 hours;
4. Have the ability to understand and voluntarily sign informed consent;
5. Have good compliance and are willing to complete all follow-up required by this program.
Exclusion Criteria:
1. Secondary insomnia: including sleep disorders (restless leg syndrome, periodic limb movement disorder, sleep-related breathing disorders, etc.), physical diseases, mental disorders, psychoactive substance abuse;
2. suffering from photosensitive dermatitis, epilepsy and other diseases that are not suitable for flash stimulation;
3. Alcohol, coffee, or drug abusers in the past 6 months;
4. Mental illness: such as anxiety, depression, schizophrenia and post-traumatic stress disorder caused by insomnia;
5. Used drugs or health products that regulate sleep function or affect sleep within 14 days before enrollment or less than 5 drug half-lives;
6. Taking drugs that may impair cognitive ability, such as anticholinergic drugs, memory enhancing drugs, etc., within 7 days before enrollment;
7. the subject is unable to complete the test or follow-up;
8. suffering from other neurodegenerative diseases;
9. There are endoplants in the body that cannot be examined by MRI;
10. Inability to lie flat;
11. Other situations in which the researcher considers it inappropriate to participate in the study.
Primary outcome measure(s)
Brain glymphatic function — The first day after treatment The gBOLD-CSF coupling strength is improved in PD patients treated with 40Hz flash stimulation.
Trial sites (1)
Facility
City
Region
Status
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou
Zhejiang
More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.